CTx001 is an investigational gene therapy currently in clinical development for the treatment of Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). 

Complement Therapeutics is committed to conducting rigorous clinical trials to evaluate the safety and potential benefit of CTx001. These studies are essential to support regulatory review and, if successful, to make the therapy available to patients more broadly. 

At this time, CTx001 is only available to patients participating in Complement Therapeutics–sponsored clinical trials. We are not currently accepting requests for expanded access, also referred to as compassionate use or pre-approval access. Expanded access is sometimes offered at later stages of development, when additional clinical data are available. 

If you require any further information regarding our Expanded Access Policy, please contact us through expandedaccess@complementtx.com. Additional information on clinical trials may also be available through public registries such as clinicaltrials.gov. 

We will continue to evaluate the possibility of expanded access as development of CTx001 progresses and as additional clinical safety and efficacy data become available. Complement Therapeutics reserves the right to revise this Expanded Access Policy at any time in accordance with the 21st Century Cures Act.